Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD
L. M. Fabbri, B. Van de Maele, B. Lemmens, C. Martin, R. Horton, M. Dolker, T. Overend (Modena, Italy; Oostende, Belgium; Amboise Cedex, France; Horsham, United Kingdom; East Hanover, United States Of America)
Source: Annual Congress 2009 - New bronchodilators
Session: New bronchodilators
Session type: Thematic Poster Session
Number: 2027
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. M. Fabbri, B. Van de Maele, B. Lemmens, C. Martin, R. Horton, M. Dolker, T. Overend (Modena, Italy; Oostende, Belgium; Amboise Cedex, France; Horsham, United Kingdom; East Hanover, United States Of America). Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD. Eur Respir J 2009; 34: Suppl. 53, 2027
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009
Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Source: Eur Respir J 2011; 37: 273 Year: 2011
Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Cardiac safety of indacaterol, a novel once-daily bronchodilator, in COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
LATE-BREAKING ABSTRACT: Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE study Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012
Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD Source: Eur Respir J 2011; 38: 797-803 Year: 2011
Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
AMPLIFY: efficacy of aclidinium vs tiotropium in COPD Source: International Congress 2018 – COPD management Year: 2018
Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008